Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Local intracoronary Rosiglitazone treatment induces a vasoprotective gene expression profile and complete reendothelialization in a porcine in stent-restenosis model (2010)

    Art
    Poster
    Autoren
    Utchil, SI
    Dang-Heine, C
    Klinowski, J
    Bösel, D
    Deiner, C
    Schultheiss, HP
    Pels, K
    Kongress
    ACC 59th annual scientific session
    Atlanta/USA, 14. – 16.03.2010
    Quelle
    Journal of the American College of Cardiology; 55(10)
    ISSN: 0735-1097
    Sprache
    Englisch
    Kontakt
    Institut für Veterinär-Physiologie

    Oertzenweg 19 b
    14163 Berlin
    Tel.+49 30 838 62600 Fax.+49 30 838-62610
    email:physiologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Background: Implantation of Drug-eluting stents (DES) is associated with delayed reendothelialization and endothelial dysfunction and thus may contribute to in stent-restenosis and late stent thrombosis. Rosiglitazone activates PPARgamma, a transcription factor involved in the control of inlammation, apoptosis and cell proliferation. We hypothesized that local rosiglitazone treatment using coated stents (RDES) improves reendothelialization by different gene expression of vasoactive and vasoprotective genes, regulating vascular tone, growth and endothelial function in comparison to Bare Metal Stent (BMS).
    Methods: In 5 pigs, RDES and BMS were randomly implanted in coronary arteries with an overexpansion (ballon/stent to artery ratio 1.3-1.5:1) in order to disrupt the endothelial layer and to induce inlammation and neointimal hyperplasia. The expression of vasoactive and vasoprotective genes (eNOS, C-natriuretic Peptide (CNP), adiponectin, endothelin-1) were evaluated after 3 months by quantitative real time RT-PCR. Additionally, endothelial expression of CD31 was analyzed by immunohistochemistry.
    Results: (see figures)
    Conclusions: 3 months after implantation of RDES not only reendotheliazation was complete, but also the endothelium appears functional, supported by a beneficial vascular gene expression profile in comparison to BMS. Intracoronary rosiglitazone treatment therefore may prevent in stent-restenosis and late stent thrombosis.